How did CDIO's revenue and expenses trend in Q4 2024?

Cardio Diagnostics Holdings (CDIO) experienced a net loss of approximately $1.41 million in Q4 2024, compared to a net loss of $1.932 million in the same period of the previous year, indicating a slight improvement in financial performance. However, the company's revenue for Q4 2024 was not disclosed. 1. **Revenue Trend**: The company's revenue for the three months ended September 30, 2024, was $6,580, which is lower than the revenue of $10,030 for the same period in 2023. This suggests a decline in revenue over the past year. 2. **Expense Analysis**: CDIO's operating expenses for the three months ended September 30, 2024, were $1,415,547. This includes general and administrative expenses of $1,353,439 and sales and marketing expenses of $52,059. The company's net loss for the same period was $1.412 million. 3. **Comparative Insights**: When compared to the nine months ended September 30, 2024, the company's revenue increased from $11,755 in Q3 2023 to $30,378 in Q3 2024, indicating a seasonal or progressive increase in revenue over the year. However, the net loss for the nine months ended September 30, 2024, was $6.864 million, which is slightly lower than the net loss of $6.987 million in the same period in 2023. 4. **Future Prospects**: Despite the challenges, CDIO has secured final CMS pricing determinations for its PrecisionCHD and Epi+Gen CHD tests, which could potentially lead to increased revenue as the tests are integrated into Medicare services. The company's innovative solutions and the favorable pricing decisions could pave the way for improved financial performance in the future.